The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021.
“In my mind, these [data from CARTITUDE-1] were the best results that have ever been shown in this truly triple-class refractory, 6 prior lines of therapy population. This is the most aggressive and the most responsive and efficacious therapy, as a single agent in refractory multiple myeloma treatment, that we've ever seen.”
Ciltacabtagene autoleucel (cilta-cel) produced deep and durable responses in heavily-pretreated patients with multiple myeloma, according to data from the phase 1/2 CARTITUDE-1 study (NCT03548207) presented at the 63rd Annual American Society of Hematology (ASH) Meeting, December 11-14, 2021, by Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California San Francisco, and co-leader, Cancer Immunology & Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center.1,2
Investigators found that the 97 participants treated with cilta-celin the CARTITUDE-1 study had an overall response rate of 98% and that of 61 evaluable participants with minimal residual disease, the progression-free survival rate at 2 years was 100%. Also presented at ASH 2021 were positive results in a less-pretreated population.3
GeneTherapyLive spoke with Martin to learn more about the data from CARTITUDE-1 presented at ASH 2021. He discussed the positive results and cilta-cel's potential in this population.